Trial Profile
Phase I Study of the Safety and Efficacy of CD19-CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Mar 2022
Price :
$35
*
At a glance
- Drugs Anti CD19 CAR T cell therapy BioceltechTherapeutics (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Bioceltech Therapeutics
- 01 Mar 2022 Results from rom 5 clinical trials (NCT03173417, NCT02546739, NCT03671460, ChiCTR-ONC-17012829, and ChiCTR1800016541) assessing Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia published in the Cancer Immunology Immunotherapy
- 08 Dec 2020 Results of an analysis from five clinical trials: NCT03173417, ChiCTR-ONC-17012829, NCT02546739, ChiCTR1800016541 and NCT03671460 presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 06 Nov 2019 Results assessing analysis of factors predicting treatment response of CD19-targeted CAR-T cell therapy in patients with B-Cell Acute Lymphoblastic Leukemia released at the 61st Annual Meeting and Exposition of the American Society of Hematology